| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.0 | 0.0 |
| Net income | -8.1 | -7.8 |
| EPS (diluted, $ a share) | $-0.16 | $-0.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +162.5% |
|---|
10-Q filed with the SEC, NASDAQ: SERA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sera Prognostics, Inc.: key numbers
- Share price
- $1.94Close, Nov 16
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sera Prognostics, Inc.
All →Sera Prognostics Financial Results
Sera Prognostics reported Q3 2026 financial results, highlighting a 54% sequential increase in PreTRM test volume and a five-fold increase since Q1 2026. The company secured Medicaid coverage for its test in Florida, following a similar win in Illinois, and ended the quarter with $72.8 million in cash and marketable securities.
- Term
- Q3 2026
“The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution. We delivered strong growth in physician adoption and test volume, saw expanded reimbursement through a second state Medicaid coverage win in Florida, advanced our commercial payer initiatives, and continued to strengthen our clinical and health economic evidence base.”
Zhenya Lindgardt, President and Chief Executive Officer
Sera Prognostics CMO Tiffany Eul Davis Inglis Sells $16.3K of Stock
Tiffany Eul Davis Inglis, CMO, sold 8,024 shares of Sera Prognostics, Inc. at $2.03 a share, worth $16.3K in total on Oct 12, 2026. Shares held after the trade: 83,565 (-8.8%).
- Value
- $16.3K
- Shares
- 8,024
- Price
- $2.03
- Role
- CMO
- Holding change
- -8.8%
- Trade date
- Oct 12, 2026